Health and Fitness
Moisturizing Intimate Gel Mucogyne Test: No Verified Data
The moisturizing intimate gel Mucogyne reader test of 10 people has no published protocol, lab data or regulator filing, unlike agency-run product tests.
The claim that 10 readers tested a moisturizing intimate gel marketed as Mucogyne is circulating as consumer news. On the available record, it is unconfirmed. No test protocol has been published, no instrumental moisture readings have been disclosed, no named dermatologist or gynaecologist is attached to the panel, and no regulator has confirmed a product filing.
That distinction is not pedantry. The difference between a reader panel and a consumer-agency test is the difference between an anecdote and a health claim. Intimate-care products are used on mucosal tissue, where ingredient disclosure, labelling accuracy and adverse-event reporting carry more weight than scent, texture or packaging.
One point should be stated plainly for readers: the source material supplied for this article contains no primary documentation of the Mucogyne trial. The available sources cover body lotions, facial moisturizers for men, women and teenagers, and e-readers. None names Mucogyne, the 10 readers, the gel’s ingredients, the length of the trial or the measures used. That gap between the claim and the evidence is the story.
Why The Moisturizing Intimate Gel Mucogyne Reader Panel Proves Little
Ten testers is not disqualifying in itself. The Guardian’s review of body lotions used five testers, 15 products and three weeks, guided by three licensed dermatologists, and it published its method, its tester age range, its survey categories and the fact that samples were supplied by the companies, as detailed in the Guardian’s testing notes.
A panel becomes evidence only when a reader can see who tested, for how long, on which body site, against what baseline, and what counted as success. A moisturizing claim requires at least a before-and-after measure of skin hydration and of moisture loss. A satisfaction score measures preference, not moisture.
What A Verified Moisture Test Looks Like
A published benchmark exists. The Korea Consumer Agency surveyed 1,500 consumers to select eight frequently bought creams, purchased them with its own funds, and measured moisture with instruments in a room with strictly controlled temperature and humidity, as reported by SBS News.
The results contradicted price. Cetaphil Moisturizing Cream cost 66 won per millilitre and topped user satisfaction among 50 men and women in their 20s to 50s, while La Roche-Posay Cicaplast Baume B5+, at 456 won, was 6.9 times more expensive and scored lowest. Only two of the eight products, Aestura and Innisfree, won top grades for both replenishing moisture and reducing moisture loss, measured on 22 women at three and six hours. All eight passed safety screening for seven heavy metals and six preservatives, including parabens, and label volume checks.
The agency also flagged a limitation that bears directly on any intimate-gel claim: its readings came from the inner forearm, not the face. Whether a Mucogyne panel tested mucosal tissue or forearm skin has not been disclosed.
Other outlets show similar rigour at different scales. Women’s Health tested 37 moisturizers over a year with four board-certified dermatologists, checking seasonal and travel performance, per its methodology. Men’s Health routed its list through a dermatologist panel and separated occlusives, humectants and emollients, while warning that sensitive skin should avoid alcohol, artificial fragrance, dyes and parabens such as preservatives, as set out in its buying guide.
The African Evidence Gap
No African consumer agency scorecard, national regulator statement or laboratory dataset for this product appears in the material reviewed. That is an observation about the available record, not a finding that none exists.
The structural point stands. For readers in Lagos, Nairobi, Accra or Johannesburg, the only public claim attached to this product is a 10-person panel with unpublished methods. Where imported personal-care lines reach shelves faster than laboratory capacity can audit them, a reader panel can function as marketing. It is not verification.
Three outcomes are plausible, and all are forecasts rather than reported events. First, the brand publishes a full protocol, an ingredient list, patch-test data and a named laboratory, which would allow independent assessment. Second, a national regulator or independent laboratory tests the product and publishes results, as the Korean agency did. Third, the claim fades without documentation, leaving consumers with word of mouth.
The test of credibility is concrete: a pre-registered protocol, a named testing facility, a complete ingredient declaration, a stated application site, and a reporting channel for adverse reactions. Absent those, a count of 10 readers is a marketing figure rather than a measurement.
The Big Picture
Consumer journalism has learned to distrust price as a proxy for quality. The Korean data showed the cheapest cream outperforming the most expensive by a wide margin, and the Guardian’s panel found a budget cocoa butter lotion outlasting premium alternatives on hydration, even as its pump failed. Those findings were credible because the methods were visible.
The moisturizing intimate gel Mucogyne arrives without that scaffolding. Until a protocol, a laboratory and a regulator-visible ingredient list are produced, readers should treat the 10-person panel as an unverified claim about a product applied to sensitive tissue, not as tested fact. The standard already exists in other markets. Applying it here is the minimum a health-adjacent category should meet.
Frequently Asked Questions
Has the Mucogyne reader test been independently verified?
No. The source material reviewed for this article contains no protocol, instrumental moisture data, named clinical oversight or regulator filing for the 10-reader test. The claim is therefore unconfirmed.
How do consumer agencies test moisturizers differently?
The Korea Consumer Agency bought products with its own funds, surveyed 1,500 consumers to select eight creams, measured moisture instrumentally in a temperature- and humidity-controlled room, tested for heavy metals and preservatives, and published its results, including the limitation that readings came from the inner forearm rather than the face.
What should consumers look for before trusting an intimate-care moisture claim?
A published test protocol, a named laboratory, a complete ingredient declaration, the body site tested, the duration of use and a channel for reporting adverse reactions. Without these, a small reader panel reflects preference rather than measured hydration.
Health and Fitness
Nigeria’s Health Funding Crisis: A Remedy Nobody Has Tested
Nigeria’s health funding crisis has a four-year deadline. What the evidence on domestic financing actually shows, and what remains unproven.
Nigeria’s health funding crisis now has a name, a number and a deadline. The name is donor dependency. The number is a projected $280 million reduction in United States support. The deadline, according to the federal government’s own assessment, falls within four to five years.
That framing matters. The remedy being promoted across African health ministries, domestic financing, rests on a simple argument: countries should fund their own nurses, vaccines and laboratories instead of waiting on Washington. Parts of that argument sit on solid evidence. Parts of it are being sold with more confidence than the data carries.
What The Health Funding Crisis Looks Like In Hard Numbers

Speaking at the opening of the 67th National Council on Health in Lafia, Nasarawa State, the coordinating minister of Health and Social Welfare said development assistance for health had declined sharply in 2025. President Bola Ahmed Tinubu approved additional resources to protect gains in HIV, tuberculosis, malaria and polio immunisation.
The minister was blunt about the arithmetic. “If the US exits and we don’t increase our domestic financing, we’ll be left with a very large gap,” he said. “Sovereignty is only possible if we put our money where our mouth is.”
Independent analyses put the size of that gap in perspective. A KFF review of US and Global Fund reductions across the 29 countries that signed bilateral agreements estimates combined cuts of $4.3 billion between 2026 and 2029, a 24 percent drop, with 77 percent of it driven by the United States. Nigeria’s projected reduction, $280 million, is the third largest in dollar terms after Uganda and Mozambique.
A separate analysis by Public Citizen and Partners in Health, reported by Health Policy Watch, found the US plans to cut health funding to 18 countries by 59 percent of pre-2025 levels by 2030, roughly $2 billion. Rwanda faces a 97 percent reduction. Liberia, 84 percent. Burundi, 78 percent. Madagascar, 77 percent. Sierra Leone, 71 percent.
The continental picture is starker still. A Guardian report on the Accra Reset initiative notes that external financing for health in Africa contracted by close to 70 percent between 2021 and 2025. The dissolution of USAID pushed Nigeria to absorb 28,000 health workers previously employed by the agency, at a cost of $200 million.
What The Evidence Actually Establishes
Here is where the domestic financing argument splits into strong and weak claims.
The budget trend is documented. State health budgets rose from N1.97 trillion in 2023 to more than N3.3 trillion in 2026. That is a real number, on the record, announced at the sector’s highest policymaking body under the National Health Act 2014.
The service outputs are documented too. Skilled deliveries in facilities supported by the Basic Health Care Provision Fund rose from 4.8 million in 2023 to almost eight million by mid-2026. Fourth antenatal visits climbed from six million to 8.7 million. The share of BHCPF-supported facilities in hard-to-reach communities with at least two midwives or community health workers jumped from 12 percent to almost 91 percent. Health insurance enrolment moved from 16 million to nearly 24 million Nigerians in three years.
Those are administrative counts. They are not impact evaluations. Nothing in the government’s reporting isolates domestic spending as the cause of any health outcome, and no controlled comparison is offered. The proposition that more domestic money produces better health is plausible and consistent with these figures. It is not yet proven by them.
The minister’s own caveat exposes the soft spot. Allocations are not releases. A state can budget its share of N3.3 trillion and disburse a fraction of it. The health funding crisis, in other words, is a disbursement problem as much as an allocation one, and the government’s own timeline runs into 2027, an election and transition year when budget discipline historically weakens.
How To Read The Remedy Safely

The bilateral agreements come with conditions that Nigeria’s public discussion has barely touched. Countries must co-finance activities the US identifies as priorities, such as outbreak detection, epidemiologists and data capture. Those may not match what a health ministry would fund first, such as nurses and midwives.
The penalties are explicit. If Ethiopia, Kenya, Mozambique, Cameroon and Malawi miss co-financing targets, the US reduces funding by $1 for every $1 shortfall. Uganda and Cote d’Ivoire face a 2:1 reduction. The co-investments must be funds raised directly and may not include other donors or multilateral money. Malawi would have to mobilise new funding equal to 56 percent of its total health expenditure to meet its commitment.
The workforce consequences are already projected. Seven African countries will have fewer health workers by 2030. The region currently has only 46 percent of the health workers it needs, with a projected shortage of 5.85 million by the end of the decade.
What the source material does not contain is Nigeria’s own co-financing obligations, penalty terms or priority areas. The minister said the memorandum was discussed with the Nigeria Governors’ Forum and is publicly available. Until those terms are examined line by line, any claim that the gap can be closed on schedule remains a projection rather than a finding.
Risks And Alternatives Worth Weighing
The equity gap is the clearest risk. The latest household survey shows skilled health workers attending fewer than four in 10 rural births, against seven in 10 in urban areas. An increase in aggregate spending that does not move that number is not a fix.
The Emir of Shonga, HRH Dr Haliru Ndanusa Yahaya, made the sharper structural point at the same council. The problem, he argued, is not a lack of commitment but poor coordination, and the Federal Government has no territory of its own on which to implement healthcare programmes. A single national compact involving all governors, one plan and one budget, has made reform smoother. He also warned that as partners withdraw, Nigeria will have to stretch its own resources further.
Alternatives already in motion include local production. Ten factories and production lines have been commissioned, six of them this year, backed by more than N24 billion in tax waivers under a June 2024 executive order. The Accra Reset makes the strategic case: Africa produces less than 1 percent of its vaccines while carrying about 25 percent of the global disease burden, which turns regional manufacturing into a financing strategy in its own right.
Areas the ministry itself admits are behind schedule, including sodium reduction, cosmetic safety, contraceptive prevalence, laboratory management and quality improvement, are cheaper to fix than to defer.
Is Domestic Financing Worth Trying?
Yes, with conditions attached. Domestic financing is the right direction and the only durable one, but the evidence behind it is strong on direction and thin on proof. The health funding crisis will not be closed by goodwill, or by resolutions passed at councils, or by an increase in nominal budgets that never leaves the treasury.
What would settle the question is boring and measurable: quarterly release of appropriated funds, published terms of the agreements that set the deadlines, and honest reporting on whether rural births are attended by skilled hands. The remedy is worth trying. It is not yet worth claiming as a cure.
Frequently Asked Questions
How much US health funding is Nigeria set to lose?
A KFF analysis of the bilateral agreements estimates Nigeria’s reduction at $280 million, the third largest in dollar terms among the 29 countries studied, after Uganda at $370 million and Mozambique at $356 million. The cuts are phased between 2026 and 2029.
Is domestic financing proven to improve health outcomes?
Not yet proven. Nigerian state health budgets rose from N1.97 trillion in 2023 to more than N3.3 trillion in 2026, and service counts such as skilled deliveries and antenatal visits improved over the same period. But those are administrative figures, not impact evaluations, and they do not isolate domestic spending as the cause. The direction of the evidence is reasonable; the causal proof is missing.
What is the biggest practical risk in the transition away from US aid?
Release of funds, not allocation. The health minister noted that allocated money must actually be disbursed, and the transition timeline runs into 2027, an election and transition year. A second risk is equity: skilled health workers attend fewer than four in 10 rural births in Nigeria, against seven in 10 urban births.
Health and Fitness
Zimbabwe’s HIV Gains Face A Test Among Young People
Zimbabwe’s HIV gains face a double test: a rejected $367m US health deal and a young generation that never saw the wards full.
Zimbabwe’s HIV gains are usually told as a single number: new infections down from an estimated 79,000 in 2010 to 15,000 in 2023, according to UNAIDS figures reported by Al Jazeera. Among people aged 15 to 24, the fall ran from roughly 27,000 to 4,400.
Those are estimates, not registries, and they describe a past decade rather than the next one. Two developments now test them at once: the unravelling of the financing model that paid for much of Zimbabwe’s treatment and prevention work, and a cohort of young people who never saw the wards that taught their parents to fear the virus.
What Zimbabwe’s HIV Gains Actually Rest On

The financing side is documented. The US embassy in Harare says Washington provided more than $1.9bn in health funding to Zimbabwe over two decades, and that 1.2 million men, women and children currently receive HIV treatment through US-supported programmes, the BBC reported.
That figure is the crux. Zimbabwe’s HIV gains were never self-financed at scale. They were co-financed, and the co-financier has changed its terms.
Since returning to office, US President Donald Trump has slashed foreign aid and closed USAID, arguing its spending was wasteful. His administration says it is pursuing government-to-government deals instead. The US embassy in Zimbabwe says 16 African countries have signed such pacts, representing more than $18.3bn in new funding.
A Rejected $367m Deal And A Text Nobody Has Published
Zimbabwe is not among the 16. It rejected a five-year package worth $367m (£272m). The decision became public after a government memo dated December was leaked; the BBC reports that President Emmerson Mnangagwa described the arrangement as “lopsided”.
The two governments give different accounts of why. Government spokesman Nick Mangwana said Washington wanted access to biological samples for research and commercial gain without sharing the benefits — vaccines, diagnostics or treatments — that might flow from them. In essence, our nation would provide the raw materials for scientific discovery without any assurance that the end products would be accessible to our people should a future health crisis emerge,” he said.
US ambassador Pamela Tremont framed the loss differently. “We believe this collaboration would have delivered extraordinary benefits for Zimbabwean communities especially the 1.2 million men, women and children currently receiving HIV treatment through US-supported programmes,” she said, adding that Washington would “turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe.”
Separating confirmed fact from claim matters here. Confirmed: the offer was rejected, the sum involved, and the embassy’s winding-down statement. Contested: the precise scope of the data-sharing clause. Neither government has published the agreement text. Zimbabwe’s account of the terms rests on its own officials; Washington’s rests on its embassy.
The dispute is not isolated. The BBC reports that Kenya’s High Court suspended a similar health funding agreement after a consumer rights lobby filed a case citing concerns about the safety of Kenyans’ health data. Mangwana linked the deals to the US withdrawal from the World Health Organization, pointing to the WHO’s Pathogen Access and Benefit Sharing scheme as the model Zimbabwe would prefer.
Why Young People Are The Weak Point
Zimbabwe’s HIV gains are exposed on a second, quieter front. UNAIDS estimated that 210,000 adolescent girls and young women aged 15 to 24 acquired HIV worldwide in 2023. About 160,000 of those infections were in sub-Saharan Africa, and nearly 60 percent of the global total occurred in Eastern and Southern Africa.
In Zimbabwe, Dr Misheck Ruwende, a family physician and stigma-reduction advocate, said in a public address on Twitter in September, followed by Al Jazeera, that the country risked reversing progress “at a time we have the best options to prevent HIV, from rapid testing, PrEP, condoms, PEP to injectables.”
The evidence for a shift in youth attitudes is thinner than the anecdote. Shaun Moyo, a 48-year-old nurse who began at Parirenyatwa Hospital in Harare in the late 1990s and still works locum shifts at two public hospitals, recalls: “In the 90s every weekend was a trek to cemeteries, not weddings.” She cites a Facebook exchange among her son and his friends in which one comment suggested high blood pressure was worse than HIV. That is one observation, not a survey; the sources contain no national youth-attitude data.
The Tools Exist, The Delivery Is The Test
Prevention technology has moved faster than the messaging around it. The PURPOSE 1 Phase 3 trial examined lenacapavir, an injectable given twice a year. In the primary analysis, none of the 2,134 women who received the drug acquired HIV. Dr Linda-Gail Bekker, a co-author of the trial report, argues communication has not kept pace: “Beating the old drum about the horrors of HIV, and shouting to youths about condoms is not necessarily going to cut it.”
Delivery is being rebuilt from the ground up. Angela Gutu, a 23-year-old peer educator, organises pop-up services with the Harare municipality, the health ministry, NGOs and churches at markets, transport hubs, university campuses and sporting events, offering self-testing kits and condoms. “It’s about speaking young people’s lingo, taking away the HIV stigma,” she said.
Dr Innocent Hove, Provincial Medical Officer for Harare Metropolitan Province, told reporters at an August meeting that HIV among young Zimbabweans was an urgent priority, citing decentralised PrEP, PEP, testing and treatment, plus mobile trucks serving informal mining communities.
Funding pressure already reached this layer. UNAIDS reported in March 2025 that disruptions to US-funded HIV programmes in Zimbabwe had affected services for key populations, including PrEP, testing and counselling.
The Bigger Picture
Zimbabwe’s government has not closed the door. Mangwana said the refusal “should not be misconstrued as anti-American sentiment” and welcomed continued dialogue. The Zimbabwe College of Public Health Physicians, while saying it understood the government’s concerns, argued that disputes over data governance “can often be addressed through technical clarification and negotiated safeguards.”
That is the test now running. Zimbabwe’s HIV gains were built on a financing arrangement being renegotiated country by country, and on prevention behaviour every new cohort has to learn for itself. One pillar is being repriced. The other cannot be bought at all.
“My generation was born with the best array of HIV prevention tools,” said Bongani, who plans to volunteer as a peer educator through the health ministry’s programme in January. “It’ll be a tragedy if AIDS deaths make a dramatic comeback due to our reckless behaviours.”
Frequently Asked Questions
Why did Zimbabwe reject the $367m US health deal?
According to government spokesman Nick Mangwana, Washington demanded access to biological samples for research and commercial gain without guaranteeing that any resulting vaccines, diagnostics or treatments would be shared with Zimbabwe. President Emmerson Mnangagwa reportedly called the deal “lopsided” in a December memo that was later leaked. The full agreement text has not been published by either side.
How much has the US spent on health in Zimbabwe?
The US embassy in Harare says Washington has provided more than $1.9bn in health funding to Zimbabwe over the last two decades, and that 1.2 million people currently receive HIV treatment through US-supported programmes.
How much have new HIV infections fallen in Zimbabwe?
UNAIDS estimates annual new infections fell from 79,000 in 2010 to 15,000 in 2023. Among people aged 15 to 24, infections declined from about 27,000 to 4,400 over the same period. These are modelled estimates rather than counted case registries.
Health and Fitness
Hair Dye Safety: What Works, What Doesn’t, What’s Unproven
A practical hair dye safety guide: patch tests, bleach timing and scalp care, using celebrity colour changes as a cautionary case study.
The outcome you want is straightforward: a new colour that looks good, holds up, and leaves your scalp where it belongs. The fastest way to lose it is to copy a celebrity’s finished result while skipping the part of the process nobody photographs. That gap is where hair dye safety usually fails.
Jacob Elordi spent a weekend in New York City hiding his. According to Elle, the actor was photographed on two dates with Kendall Jenner, at Paranormal Activity on Broadway on Saturday and outdoors in fall layers on Sunday. He wore a beanie both times and added a hoodie on the second day for extra coverage. Even so, a patch of blond showed at the back of his hat. He has not said why he changed colour, and he has not shown the full look.
That concealment is a useful starting point for a health conversation, because it separates the outcome from the process. Blond is a result. Testing, timing and a professional who knows what your scalp can take is the process. Most hair damage happens when someone chases the first without the second.
Why Hair Dye Safety Matters More Than The Shade
Your scalp is skin. It absorbs, it reacts, and it remembers.
A dye applied to a calm scalp and the same dye applied to skin that is already irritated or freshly relaxed are not the same event. Dermatologists and dye manufacturers have long recommended patch testing before application, and most box kits carry the instruction on the leaflet. Allergic reactions to hair colour are a recognised, documented problem, not a freak accident. This is the strong end of the evidence: contact allergy to dye chemicals exists, it can develop after years of uneventful use, and once it appears it tends to persist.
The weak end is where most online argument lives. Questions about repeated dye exposure and long-term cancer risk have been studied for decades with mixed results. Research is still ongoing. No single study justifies panic, and no single study justifies dismissal either. Anyone who tells you the matter is settled is selling something.
What the celebrity coverage does establish is narrower and more reliable: professionals do not apply colour to an untested scalp, and they do not treat colour as a five-minute decision.
Hair Dye Safety Steps That Actually Hold Up
First, patch test 48 hours ahead. A small amount of dye behind the ear or on the inner forearm, left alone, tells you what your immune system thinks before your whole head finds out. Skip this and you are gambling on a reaction you cannot undo.
Second, be honest about your hair’s history. A relaxer, a recent henna application or a bleach job from six weeks ago changes what the next chemical can safely do. Salons in Lagos, Accra and Nairobi handle this daily, and the good ones ask. If yours does not ask, volunteer it.
Third, treat bleach as the serious step it is. Lifting dark hair to blond means removing pigment, and removing pigment means chemical stress on the shaft. Doing it in one sitting to save time raises the odds of breakage and scalp burns. Two sessions with a gap between them is slower, and safer.
Fourth, know what natural means on a label. Henna and herbal dyes are not automatically gentler. So-called black henna has been repeatedly flagged by dermatologists and regulators because it is often mixed with the same dye chemicals used in conventional colour, and applied to skin rather than hair. A plant on the box is not a safety guarantee.
Fifth, space out chemical services. Colour, relaxer and bleach inside the same fortnight is a schedule for damage. Give the scalp weeks, not days.
The Mistakes That Undo Everything

The biggest one is chasing a specific shade in a single appointment. The second is dyeing over an irritated scalp because an event is coming. The third is assuming a salon visit is protection. A salon reduces risk. It does not remove risk, and no stylist can test your immune system on your behalf.
None of this is exotic. Hair dye safety is mostly bookkeeping: what your scalp has already been through, and when.
It is worth noting that AOL reported Jenner’s platinum bob at the end of October, worn for a Paris, Texas Halloween costume. The same report notes she had gone blonde before, for looks referencing Pamela Anderson and Marilyn Monroe. Even with professional teams, this is a repeated, staged exercise across years, not one dramatic afternoon. AOL also reported that actor Paul Anthony Kelly went bleach blonde for a television role, in his case with highlights styled around the part rather than a full-lift from dark.
Meanwhile, AOL UK reports that Olivia Jade has been photographed in New York with art dealer PC Valmorbida following her reported split from Elordi. Personal lives move quickly. Scalp recovery does not.
Your First Step Today
Before you book anything, arrange a patch test. If you are using a box dye, test with the product you intend to apply, not a different brand. If you are going to a salon, ask to be tested before the appointment, and if they refuse, take your scalp somewhere else. That single step is the difference between hair dye safety being a phrase in an article and something you have actually done.
The realistic result is a colour you wanted, on a scalp that is not itching, weeping or shedding. You will not get certainty about every long-term question, because nobody can give you that today. What you get is control over the risks that are known and manageable, and a habit of not treating a preliminary headline as a diagnosis.
Frequently Asked Questions
Do I really need a patch test before dyeing my hair?
Yes. Patch testing 48 hours ahead is standard guidance from dye manufacturers and dermatologists. It will not predict every reaction, but it is the cheapest way to find out whether your skin tolerates a product before it goes on your whole scalp.
Is hair dye linked to cancer?
The research is mixed and still ongoing. Studies over several decades have not produced a settled answer, and no single study justifies either panic or dismissal. The risks that are well documented and manageable are skin-related: irritation and contact allergy.
Are natural or herbal dyes safer than conventional ones?
Not automatically. Products marketed as black henna, for example, have been repeatedly flagged because they are often mixed with the same dye chemicals found in conventional colour. Read the ingredient list rather than the front of the box.
-
Car Reviews2 weeks ago
1955 Chevy Bel Air Restomod: What SEMA Really Proves
-
Savings & Investing3 weeks ago
Hidden Medicare Fees Draining Your Retirement Savings
-
Car Reviews4 weeks ago
Ford Bronco ORV Package: $18,995 Ownership Reality Check
-
JAMB & WAEC4 weeks ago
JAMB Admission Process: What Changed And What Is Still Talk
-
Movies & TV4 weeks ago
Silo Season 1 Ending Explained: What the Showrunner Said
-
Movies & TV3 weeks ago
Wizkid Starboy Desire Ft Banky W Shaydee: Fact Or Fan Fiction?








